Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

AM-0216

  Cat. No.:  DC11182  
Chemical Structure
1202761-92-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent.
Cas No.: 1202761-92-9
Chemical Name: 1-((1-(2-amino-5-chloropyrimidin-4-yl)indolin-6-yl)ethynyl)cyclopentan-1-ol
Synonyms: AM0216
SMILES: C(C#CC1=CC2=C(C=C1)CCN2C1C(Cl)=CN=C(N)N=1)(O)1CCCC1
Formula: C19H19ClN4O
M.Wt: 354.838
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent; IKKβ inhibitor MLX and dexamethasone enhances cytotoxicity of NIK-inhibitors in MMCLs with NIK-dependent NFkB activation, blocks BAFF induced NFkB activation in myeloma cells combined with IKKβ inhibitors.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC11180 Amgen 16 Amgen16 is a highly potent inhibitor of NF-κB inducing Kinase (NIK), example 294 in patent WO 2009158011 A1..
DC11181 AM-0561 AM-0561 (AM0561) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 0.3 nM..
DC11182 AM-0216 AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent.
X